Regula and Indicio Partner to Transform Identity Verification With Verifiable Credentials
30.7.2025 14:30:00 CEST | Business Wire | Press release
Regula, a global developer of identity verification (IDV) solutions and forensic devices, enters a strategic technology partnership with Indicio, a market leader in Verifiable Credential technology and decentralized identity solutions. Together, the two companies will deliver a breakthrough in portable digital trust by issuing document and biometric identity verification solutions as tamper-proof Verifiable Credentials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730663365/en/

Regula x Indicio: Bridging the gap between physical IDs and tamper-proof digital credentials
This collaboration between Regula and Indicio delivers a holistic infrastructure for creating, storing, and verifying digital identities, underpinned by the most robust verification technologies available today.
After decades of forensic expertise and innovation in document and biometric verification technology, Regula has the most complete set of ID authenticity checks and most trustworthy server-side document NFC verification available in its Regula Document Reader SDK. The solution is backed by Regula’s proprietary world’s largest identity document template database, which currently includes over 15,000 templates of IDs issued in 252 countries and territories.
With Indicio’s field-leading and award-winning decentralized identity technology, the validation of identity documents by Regula can now be transformed into user-held, tamper-proof Verifiable Credentials for instant, seamless verification. This enables both companies to provide the deepest and widest range of globally-interoperable, digital identity solutions for business and governments.
By joining forces, Regula and Indicio could deliver a solution that enables companies to deploy Verifiable Credentials across a wide range of formats, including those specified by the European Union’s Digital Identity Wallet (EUDI), Digital Travel Credentials (DTC) following International Civil Aviation Organization (ICAO) specifications, W3C credentials and the mobile document-mobile driver’s license format (ISO 18013-5, mdoc/mDL).
Indicio will offer their mobile wallet SDK customers Regula’s industry leading biometric and document verification technology to provide the highest level of identity assurance to take a leap forward in the kind of strong, seamless authentication needed for KYC, payments, digital finance, and, of course, travel and hospitality. The combination of Regula and Indicio technology is also capable of tackling the latest challenges in biometric identity fraud and generative AI deepfakes.
“This partnership transforms the way we share and verify data,” said Heather Dahl, CEO of Indicio. “The breadth and depth of Regula’s technology in document authentication is unmatched, and to be able to issue, share, and verify these documents as Verifiable Credentials provide the world with the breakthrough in digital trust it needs. We are tremendously excited to be working with Regula.”
“The global shift towards decentralized digital identity is here today, but it will bring tangible benefits only with the right technology behind it. Our partnership with Indicio bridges the gap between today’s physical documents and tomorrow’s trusted digital credentials. With Regula’s verification capabilities and Indicio’s decentralized infrastructure, organizations now have a powerful way to adopt fully portable digital identity,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about Regula’s capabilities in supporting Verifiable Credentials, including the DTC specification, visit Regula’s website. To get insights into how DTCs are created and used, read our blog article.
About Indicio
Indicio is a global leader in digital identity, authenticated biometrics, and Verifiable Credential technology with scalable solutions that organizations can rapidly deploy for increased efficiency, better user experience, and reduced cost. Our award-winning enterprise solution, Indicio Proven®, offers the widest range of interoperable decentralized identity options for global deployments, from single sign-on to seamless border crossing as well as compatibility with the European Union’s digital identity and wallet standards.
Learn more about how Indicio is using this technology to successfully transform education, finance, government, health, travel and tourism, and supply chains at indicio.tech.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250730663365/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom